FLT3 and acute myeloid leukemia: While the use of CPX-351 as a combination therapy with FLT3 inhibitors continues to be evaluated in clinical trials, the pivotal CPX-351 clinical trial and real-world studies have demonstrated that CPX-351 monotherapy may be of benefit in AML patients with FLT3 mutations; no significant differences in CPX-351 treatment outcomes were observed between patients with versus without an FLT3 mutation.